CJC-1295 no DAC + Ipamorelin Blend
CJC-1295 no DAC + Ipamorelin Blend
This research blend combines CJC-1295 without DAC (commonly called Modified GRF 1-29) and ipamorelin. Both are studied in relation to growth hormone release, but they act through different signalling pathways: CJC-1295 without DAC is related to growth hormone-releasing hormone (GHRH), while ipamorelin acts through the ghrelin receptor pathway.
In simple terms: researchers study this combination to examine how two different signals affect growth hormone release when investigated together.
Product Details
| Component | Details |
|---|---|
| Product | CJC-1295 Without DAC + Ipamorelin |
| Components | Modified GRF 1-29 and ipamorelin |
| Research category | Growth hormone signalling research |
| Amount of each component | As stated in the batch documentation |
| Total vial strength | As stated on the selected product listing |
What Is This Blend Studied For?
Preclinical and laboratory research only
GHRH signalling: Modified GRF 1-29 is used to investigate the GHRH receptor pathway involved in growth hormone release.
Ghrelin receptor signalling: Ipamorelin has been studied for its ability to stimulate growth hormone release through the growth hormone secretagogue receptor.
Combined pathway responses: Researchers may examine whether activating these pathways together changes the timing or magnitude of growth hormone signalling.
Research Use Notice
FOR RESEARCH PURPOSES ONLY. This product is intended for laboratory research and is not offered for human or veterinary use. It is not intended for therapeutic or diagnostic purposes. By purchasing, the customer acknowledges that this product is for research use only and assumes responsibility for its use.
